112 results about "Lactococcus lactis subsp. lactis" patented technology

The invention belongs to the technical field of biological medicine, and discloses lactococcus lactis HX21473 and application thereof, the lactococcus lactis HX21473 is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 20, 2025, and the preservation number is CGMCC NO.33476. The invention further discloses a preparation method of the lactococcus lactis HX21473. The invention provides a strain of lactococcus lactis HX21473 capable of efficiently expressing a foreign protein. The lactococcus lactis HX21473 has strong acid resistance, can be used as an oral vaccine live carrier, and promotes research, development and application of oral vaccines.

The invention belongs to the technical field of new energy materials, and particularly relates to a preparation method of a bamboo-based hard carbon sodium ion battery negative electrode material, which specifically comprises the following steps: (1) slicing, crushing, screening, sieving, drying and treating fresh bamboo under steam pressure to obtain bamboo powder; (2) bamboo powder and lactococcus lactis liquid are mixed and fermented, and after fermentation is completed, the bamboo powder and the lactococcus lactis liquid are washed to be neutral and dried; (3) placing the bamboo powder subjected to fermentation treatment in an inert atmosphere, heating, keeping constant temperature, and cooling to obtain a pre-carbonized sample; (4) soaking the pre-carbonized sample in a hydrochloric acid solution, continuously reacting, washing to be neutral, and drying; and (5) continuously heating the acid-washed and dried material in the step (4) in the inert atmosphere, carbonizing at a constant temperature, and cooling to obtain the final sodium-ion battery negative electrode material. The method disclosed by the invention has the advantages of remarkable environmental friendliness, low cost, simplicity and convenience in operation and the like; and the battery negative electrode material prepared by the method disclosed by the invention has excellent electrochemical performance.

The present application relates to the technical field of traditional Chinese medicine, in particular to a kind of slimming traditional Chinese medicine composition and preparation method thereof.The present application uses the raw materials such as Buzha Leaf, hawthorn, lotus leaf, immature fruit of Chinese citron, magnolia officinalis, raphanus sativus, dried orange peel, pellitory, alisma orientalis and cassia obtusifolia, after decoction, lactic acid lactobacillus lactis CICC 6242 and royi mucous lactobacillus CICC 6121 are fermented with 0.4-0.8:1 ratio, then combined enzymolysis is carried out using ginger protease and snail protease, and then 15-25wt% ethanol is used for extraction, and the composition is endowed with excellent lipid-lowering and weight loss effect.

The invention belongs to the field of microorganisms, and particularly relates to lactococcus lactis Jlus 880314 and application thereof. The strain is classified and named as Lactococcus lactis, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number of the strain is CGMCC No. 33961. Time-of-flight mass spectrometry analysis shows that nisin exists in a metabolite of the strain, and the strain can be used for producing nisin. The compound shows an excellent and wide antibacterial function in antibacterial experiments, can be used for preparing antibacterial drugs, particularly has a remarkable inhibiting effect on growth of gram-negative bacteria and fungi, can be used for preparing drugs for relieving or treating enteritis, or preparing drugs, nourishment or health care products for regulating gastrointestinal tract micro-ecological balance of people or animals, and can be used for preparing medicines for relieving or treating enteritis. The compound can also be used for preparing antibacterial food additives and / or animal feed additives. A hemolysis experiment result shows that hemolysis is avoided, toxic and side effects are small, and wide development prospects and application values are achieved.

The invention belongs to the technical field of biomedical treatment and biological fermentation, discloses a metagen composition for effectively inhibiting oral dental caries and application thereof, and aims to solve the problems of great side effect, weak effect and unknown mechanism of the existing dental caries prevention and treatment means. The composition is prepared by mixing a metagen 1 which is prepared by fermenting lactobacillus salivarius Postbio-YY with a metagen 2 which is prepared by fermenting lactococcus lactis Postbio-F3 and lactobacillus paracasei Postbio-P6 step by step. In the preparation process, the active ingredients are reserved by accurately controlling the fermentation pH, time and pasteurization parameters. The composition can be prepared into multiple dosage forms such as toothpaste and the like, can remarkably inhibit the growth of streptococcus mutans and destroy the thallus structure, inhibits biofilm and exopolysaccharide synthesis by down-regulating fimI, wcaJ and wcae genes, is safe and free of side effects, and provides an efficient scheme for decayed tooth prevention and treatment.

The invention relates to the technical field of functional microbial preparations, in particular to a biological preparation for relieving intestinal discomfort caused by alcohol and a preparation method and application thereof.The main technical scheme is that the biological preparation is prepared from, by weight, 5-20 parts of bacillus coagulans, 10-30 parts of pediococcus pentosaceus, 5-10 parts of lactobacillus rhamnosus and 0-20 parts of saccharomycetes. 0-5 parts of bifidobacterium longum and 0-5 parts of lactococcus lactis. By constructing an alcohol metabolism-intestinal protection dual-function synergistic system, specific florae such as bacillus coagulans, pediococcus pentosaceus and lactobacillus rhamnosus are scientifically compatible with functional components such as inulin and L-cysteine, alcohol is efficiently metabolized, and a carbon source is generated; the technical problems of low metabolic efficiency, weak intestinal protection and serious gastric acid inactivation of a traditional product are comprehensively solved.

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

The invention discloses a method for improving yield of branched chain aldehyde of lactococcus lactis based on regulation and control of a luxS gene and application, and belongs to the field of system biology. Gene function verification and genome scale metabolic network model analysis are creatively combined, the phenotypic effect of the luxS gene is confirmed, and more importantly, the internal action mechanism of the luxS gene is disclosed from the system level, that is, the whole metabolic network flow is influenced by regulating and controlling multiple key enzymes such as transaminase, decarboxylase, dehydrogenase and decarboxylase. The invention reveals that the quorum sensing core gene luxS has a new function of regulating and controlling synthesis of branched chain aldehyde in lactococcus lactis for the first time, and an intercellular communication system is directly linked with production of specific flavor metabolites. The invention provides a brand-new and higher-level regulation target and thought for producing flavor substances by microbial fermentation, and gets rid of the limitation that only metabolic pathway terminal enzyme is singly modified traditionally.

The application discloses a beta-1,4-xylanase mutant and a construction method thereof, and comprises the following steps: constructing a beta-1,4-xylanase recombinant expression vector; introducing the recombinant vector pNZ8048-P5-XynA into a competent lactococcus lactis by using an electrotransformation technology to construct a wild-type expression vector; on the basis, designing and constructing a multi-site mutant recombinant plasmid by using a site-directed mutation method, wherein the eighth asparagine (Asn) of the beta-1,4-xylanase is mutated into tyrosine (Tyr), the 22nd serine (Ser) is mutated into proline (Pro), and the 59th alanine (Ala) is mutated into lysine (Lys); introducing the multi-site mutant recombinant plasmid into the competent lactococcus lactis to construct a heterologous expression strain of the mutant beta-1,4-xylanase (Mut-1); and stably obtaining the mutant xylanase beta-1,4-xylanase (Mut-1) with high activity by using a metal affinity chromatography (Ni 2+ ) method. The specific enzyme activity of the mutant reaches 1929.30±5.36 U / mg, and the optimal temperature is increased by 15 DEG C compared with that of the wild type.

The invention belongs to the technical field of microorganisms, and particularly relates to a method for expressing human lactoferrin by using lactococcus lactis. The method comprises the following steps: step 1, obtaining a codon-optimized hLF gene nucleotide sequence; 2, constructing a recombinant plasmid containing the hLF gene nucleotide sequence obtained in the step 1; and step 3, transferring the recombinant plasmid obtained in the step 2 into lactococcus lactis for induced expression. The heterologous expression of the human lactoferrin hLF is realized by utilizing the lactococcus lactis, the method is low in cost, convenient and fast, and a new way is provided for high-purity and high-yield preparation of the human lactoferrin hLF.

A starter culture for the fermentation of a plant-based milk alternative is provided, which is particularly suitable for the production of a plant-based yogurt alternative. The starter culture comprises lactic acid bacteria isolated from legume plant material, especially pea plant material. Preferably, the starter culture comprises lactic acid bacteria of the species Lactobacillus rhamnosus and / or Lactococcus lactis subsp. cremoris.

The application provides a lactococcus lactis, a compound dairy product fermenting agent and application thereof, the lactococcus lactis has the functions of sweetening and flavoring, and is classified and named as lactococcus lactis Lactococcus lactis The strain has significant sweetening and flavoring characteristics, exhibits strong fructo-oligosaccharide (FOS) and acetaldehyde generation capacity in the fermentation process, can provide endogenous sweet taste and aroma flavor substances for fermented milk, and significantly improves the taste and flavor of the fermented milk.The lactococcus lactis C15 is compounded with lactobacillus casei AU9077 and lactobacillus rhamnosus AU9260 to obtain a compound dairy product fermenting agent, which has a significant synergistic effect in releasing fructo-oligosaccharide, continuously provides stable endogenous sweetening effect for fermented milk, improves the quality of dairy products, and meets the needs of consumers for healthy and flavored dairy products.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention belongs to the technical field of gene engineering, and particularly relates to an efficient electrotransformation method of lactococcus lactis BL19. According to the method disclosed by the invention, the electric shock conversion efficiency of the lactococcus lactis BL19 is remarkably improved, and a foundation is laid for genetic engineering transformation in the future.

The invention belongs to the technical field of biological medicine, and discloses lactococcus lactis HX9302 for expressing foreign protein and application, the lactococcus lactis HX9302 is preserved in China General Microbiological Culture Collection Center on January 20, 2025, and the preservation number is CGMCC NO.33477. The lactococcus lactis HX9302 is preserved in China General Microbiological Culture Collection Center on January 20, 2025; the lactococcus lactis has good acid resistance and digestive enzyme tolerance, can be used as an oral delivery live carrier of helicobacter pylori vaccines, and promotes research, development and application of oral vaccines.

The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and / or reduction of hypertension, or as a food composition or nutraceutical.

The present invention relates to a composition for treating, ameliorating and preventing liver diseases, comprising a Lactococcus lactis strain, amino acids, and a vitamin. Specifically, the present invention relates to a composition for treating, ameliorating and preventing fatty liver, comprising Lactococcus lactis KF140, tryptophan, histidine, and vitamin E.

A composition for use in treating or preventing colorectal cancer (CRC) comprising indole-3-Iactic acid (ILA) or an aminopeptidase produced by Lactococcus lactis, the aminopeptidase having a molecular

The application discloses a lactococcus lactis GL-1 and application of the lactococcus lactis GL-1 in Apostichopus japonicus breeding, and belongs to the field of aquatic beneficial microorganisms and application technologies thereof. The lactococcus lactis GL-1 is preserved in the China General Microbiological Culture Collection Center on September 16, 2025, and the preservation number is CGMCC No. 35938, and the lactococcus lactis GL-1 is isolated from traditional fermented food doubansauce. The strain can well adapt to different environments, and can be used for preparing an Apostichopus japonicus feed additive. When the number of viable lactococcus lactis GL-1 in the feed is greater than or equal to 1x10 8 CFU / g, the low-salt stress resistance of the Apostichopus japonicus can be significantly enhanced, the survival rate and growth performance are improved, the intestinal flora structure is improved, the colonization of beneficial bacteria is promoted, and immune-related pathways such as the Wnt signal pathway are activated, so that the health level of the Apostichopus japonicus is improved from multiple aspects. A safe and effective microbial solution is provided for solving the low-salt stress problem in the Apostichopus japonicus breeding.

The application discloses a Leuconostoc intestini and Lactococcus lactis composition and application, belongs to the field of microbial pharmacy, and relates to application of a Leuconostoc intestini and Lactococcus lactis composition to preparation of a drug for treating pulmonary fibrosis diseases; wherein the quantity of the Leuconostoc intestini and the Lactococcus lactis in the composition is equal in terms of colony forming units. Experimental results show that the Leuconostoc intestini and the Lactococcus lactis can effectively improve pulmonary fibrosis when being intervened alone or in combination. It is known to those skilled in the art that excessive deposition of collagen fibers is a core feature of pulmonary fibrosis diseases, and the Leuconostoc intestini and the Lactococcus lactis have a synergistic effect of inhibiting the content of lung tissue collagen in pulmonary fibrosis. Therefore, the Leuconostoc intestini and the Lactococcus lactis composition has a prospect of being developed into a drug for treating pulmonary fibrosis diseases (including idiopathic pulmonary fibrosis and secondary pulmonary fibrosis).

The application belongs to the technical field of biological gene engineering, and discloses a lactococcus lactis carrier oral vaccine for producing enterotoxigenic escherichia coli F18 pilus type and application. Four lactococcus lactis antigen surface display strains are prepared, and are mixed to perform oral immunization. The oral immunization mode is convenient to operate, avoids the stress reaction caused by injection immunization on animals, and greatly improves the immunization effect, so that the diarrhea caused by enterotoxigenic escherichia coli on piglets can be effectively prevented. 50 The application is an oral escherichia coli vaccine, and mouse immunization challenge experiment shows that all the mice can survive under the challenge dose of LD , and piglet immunization challenge experiment shows that the piglets can be 100% protected from diarrhea, which shows that the immunization group has effective mucosal immune protection ability.

The invention relates to a sensitive skin micro-ecological balance-oil control and acne removal composition and application thereof. The composition is prepared from the following components: lactococcus lactis / phellinus pharmacologically fermented product filtrate, lactobacillus / black mustard seed fermented product extract, citrus fruit extract and trifolium pretense flower extract. The weight ratio of the lactococcus lactis / phellinus pharmacologically fermented product filtrate to the lactobacillus / black mustard seed fermented product extract to the citrus fruit extract to the trifolium pretense flower extract is (0.1-8): (0.001-0.1): (0.001-0.2): (0.01-3), and the composition constructs a four-stage synergistic mechanism of flora regulation, barrier repair, oil control and fat suppression, anti-inflammation and soothing; the limitation of a single target spot in the traditional technology is broken through, and an efficient, safe and multi-dimensional regulation and control comprehensive solution is provided for oily sensitive skin micro-ecological balance.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

The application discloses a kind of 7 kinds of composition containing probiotic and its preparation method of drinkable yoghurt, belong to microbial fermentation technical field.Composition includes the combination of 2 kinds of lactic acid bacteria and 7 kinds of probiotic, lactic acid bacteria is the combination of lactococcus lactis subsp cremoris and lactococcus lactis subsp lactis;Probiotic is the combination of lactobacillus bulgaricus, streptococcus thermophilus, bifidobacterium lactis, lactobacillus acidophilus, paracasei, lactobacillus rhamnosus and bifidobacterium infantis.The composition can provide the required probiotic for children, young people, old people respectively, and in the new preparation method developed additionally, through the combination of lactic acid bacteria and probiotic, lactase pretreatment and two-step inoculation fermentation process in fermentation stage, twice post-ripening process can effectively guarantee the acidity of composition fermentation moderate, improve the stability of composition system and taste.The overall additive of the obtained product is zero addition and the flavor is excellent and high stability.

The present disclosure relates to a novel (Lactococcus lactis subsp. cremoris HEM 20103 strain useful for promoting intestinal absorption of calcium, and uses thereof. The novel Lactococcus lactis HEM 20103 strain of the present invention was confirmed to exhibit acid resistance, bile resistance, and intestinal cell adhesion ability and to have an excellent effect of promoting intestinal absorption of calcium. In addition, by increasing bone mineral content, the strain was confirmed to increase calcium metabolism, bone density, bone volume per unit volume, and cortical bone thickness and to significantly improve trabecular bone thickness, trabecular number per unit area, and trabecular spacing in osteoporosis model mice. Therefore, the strain of the present invention is expected to be widely used as a health functional food composition, a feed composition, a feed additive, and the like for promoting intestinal absorption of calcium and to have an excellent effect of preventing or treating intestinal absorption-related diseases of calcium such as osteoporosis or osteopenia.

Provided are methods for preventing or treating a chronic pain in a subject that includes administering an effective amount of a composition of Lactococcus lactis DSM 27109 to the subject.

Disclosed are microbial biomarkers and methods for accurate non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) in subjects. The microbial biomarkers include Lactococcus lactis as well as its strains and subspecies. The microbial biomarkers include Dorea sp. 5-2. The methods include measuring abundance or copy number of the one or more microbial biomarkers in a sample from the subject. The sample may be bodily fluid, mucus, or stool. Also described are methods of treating a subject with NAFLD by administering to the subject a composition containing Lactococcus lactis and / or Dorea sp. 5-2.

The invention relates to the technical field of dairy product processing, in particular to a fried cheese formula and a preparation method thereof, and the fried cheese formula comprises the following components by mass: raw milk subjected to standardization treatment, animal type chymosin, a leavening agent, calcium chloride and edible salt; the animal type chymosin is a mixture of rennase and bovine pepsase according to a mass ratio of 70: 30, the activity of the chymosin is greater than or equal to 890 IMCU / g, the addition amount of the chymosin is 43 g / t, and the chymosin is used for improving the curding efficiency and the structural stability; the leavening agent is lactococcus lactis subsp.cremoris and lactococcus cremoris, the addition amount of the leavening agent is 4D / t, and the leavening agent is used for increasing the flavor and fragrance of the product; the addition amount of the calcium chloride is 70g / t, and the calcium chloride is used for strengthening protein network crosslinking. According to the invention, the raw milk is standardized, so that the quality stability of the product is obviously improved; the thermal stability is optimized, and the eating scene is expanded; and strains capable of generating flavor substances are added, so that flavor levels are rich, the mouth feel is fine and elastic, and the eating experience is upgraded.

The present invention discloses a thermostable xylanase Lc-Xyn81 and its encoding gene and application, and relates to the field of enzyme technology. The encoding gene sequence of the thermostable xylanase Lc-Xyn81 of the present invention is shown in SEQ ID NO.1. Lc-Xyn81 xylanase exhibits optimal activity under the conditions of 75°C and pH 6.6; at 65-75°C, it maintains more than 80% relative activity and has good stability at pH 4.0-8.0. In addition, Lc-Xyn81 can be Co 2+ 、Mn 2+ 、Cu 2+ The enzyme is activated by divalent metal ions such as β-glucan and β-glucan. The enzyme is active against beechwood, corncob, and bagasse xylans, with the resulting products primarily consisting of xylobiose and xylotetrose. These products also significantly promote the growth of Lactococcus lactis. Therefore, the enzyme has great potential for application in food, feed, papermaking, bioethanol, and particularly in prebiotic production.